Pharmacological lipid-lowering therapies for primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia: a systematic review and network meta-analysis

Q: What is the clinical evidence from this study?

Study design: Systematic Review. Population: Cardiovascular disease in adults with dyslipidaemia. Intervention: Lipid-lowering therapies (statin regimens, non-statin therapies, and combination regimens) vs. Placebo/no treatment. Primary outcome: Effects and safety of lipid-lowering therapies.

Kamyar Shokraee; Brenda Bongaerts; Eylul Taneri; Camila Micaela Escobar Liquitay; Siavosh Olfati; Ana-Mihaela Zorger; Nicole Skoetz; Juan Víctor Ariel Franco

doi:10.1002/14651858.cd016387

September 16, 2026Cochrane library

Pharmacological lipid-lowering therapies for primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia: a systematic review and network meta-analysis

View at Publisher

Ask AI

Bookmark

Share

Key result

Cochrane protocol outlines network meta-analysis evaluating lipid-lowering therapies for cardiovascular disease prevention.

Why the study?

The comparative effects and safety of various lipid-lowering therapies for primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia require systematic evaluation.

Do pharmacological lipid-lowering therapies improve primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia?

Key Points

To assess and compare the efficacy and safety of various pharmacological lipid-lowering therapies for primary and secondary cardiovascular disease prevention and determine their relative rankings.
Protocol for a Cochrane systematic review utilizing pairwise and network meta-analyses of randomized interventions.
Evaluates high-, moderate-, and low-intensity statin regimens, non-statin agents, and combination drug therapies compared to each other or placebo/no treatment in adults with dyslipidaemia.
As a study protocol, empirical outcome data, event rates, effect sizes, and confidence intervals are not yet available.
The planned synthesis will establish the comparative clinical hierarchy and safety profiles of evaluated regimens for preventing cardiovascular events.

Study Design

Type

Systematic Review

Structured PICO

Do pharmacological lipid-lowering therapies improve primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia?

P

Population

Adults with dyslipidaemia for primary and secondary prevention of cardiovascular disease

I

Intervention

Lipid-lowering therapies, including statin regimens (high intensity, moderate intensity, and low intensity), non-statin therapies, and combination regimens

C

Comparator

Placebo/no treatment or other lipid-lowering therapies

O

Outcome

Effects and safety for the primary and secondary prevention of cardiovascular disease

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

This is a protocol for a Cochrane systematic review and network meta-analysis to evaluate the comparative efficacy and safety of various lipid-lowering therapies in adults with dyslipidaemia.

Abstract

OBJECTIVES: This is a protocol for a Cochrane review (intervention). The objectives are as follows: Primary To compare the effects and safety of lipid-lowering therapies, including statin regimens (high intensity, moderate intensity, and low intensity), non-statin therapies, and combination regimens, for the primary and secondary prevention of cardiovascular disease in adults, using pairwise and network meta-analysis where appropriate. Secondary To obtain an estimate of the relative ranking of these lipid-lowering therapies compared to placebo/no treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shokraee et al. (2026) conducted a systematic review in Cardiovascular disease in adults with dyslipidaemia. Lipid-lowering therapies (statin regimens, non-statin therapies, and combination regimens) vs. Placebo/no treatment was evaluated on Effects and safety of lipid-lowering therapies. This is a protocol for a Cochrane systematic review and network meta-analysis evaluating lipid-lowering therapies for cardiovascular disease prevention; no results are reported.

synapsesocial.com/papers/6aabb6b55f706d05830e53b5 https://doi.org/10.1002/14651858.cd016387

View at Publisher

Ask AI

Bookmark

Share

Pharmacological lipid-lowering therapies for primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia: a systematic review and network meta-analysis

Key Points

Study Design

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Pharmacological lipid-lowering therapies for primary and secondary prevention of cardiovascular disease in adults with dyslipidaemia: a systematic review and network meta-analysis

Key Points

Study Design

Structured PICO

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading